Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im
A phase 3 trial of Sacituzumab govitecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Gilead Sciences, active and no longer recruiting.
Overview
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) is a phase 3 interventional study registered as NCT06486441 by Gilead Sciences, with 640 participants planned, started 2024-08-28 and due to reach its primary completion in 2029-06. Interventions recorded: Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
- TrialStudy of Sacituzumab Govitecan in Patients With Solid Tumor
- TrialStudy of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
- TrialA Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- TrialSacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
- TrialPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialStudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy